Biogen’s Phase II Lupus Success Offers An Additional Viable Pipeline Asset

Businessman running up stairway to the target, Challenge,
Developing a lupus drug is a steep climb for any company, but Biogen moved a step closer

More from Clinical Trials

More from R&D